Aligos Therapeutics, Inc. Operating Expenses
Aligos Therapeutics, Inc. (ALGS) reported Operating Expenses of $29.67 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- Aligos Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $29.67M, a 51.89% increase year-over-year.
- Aligos Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $29.76M, a 52.19% increase year-over-year.
- Aligos Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $21.98M, a 3.73% increase year-over-year.
- Aligos Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $29.10M, a 35.99% increase year-over-year.
- Aligos Therapeutics, Inc. operating expenses for fiscal 2025 was $90.17M, a 3.15% decline from fiscal 2024.
- Aligos Therapeutics, Inc. operating expenses for fiscal 2024 was $93.10M, a 10.18% decline from fiscal 2023.
- Aligos Therapeutics, Inc. operating expenses for fiscal 2023 was $103.66M, a 7.02% decline from fiscal 2022.
- Aligos Therapeutics, Inc. operating expenses for fiscal 2022 was $111.49M, a 15.97% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $29.67M 10-Q · filed 2026-08-06 | $59.43M 10-Q · filed 2026-08-06 | $81.41M derived: sum of 3 quarters · filed 2026-08-06 | $110.51M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $29.76M 10-Q · filed 2026-05-07 | $51.74M derived: sum of 2 quarters · filed 2026-05-07 | $80.84M derived: sum of 3 quarters · filed 2026-05-07 | $100.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $21.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $51.09M derived: sum of 2 quarters · filed 2026-03-05 | $70.62M derived: sum of 3 quarters · filed 2026-08-06 | $90.17M 10-K · filed 2026-03-05 |
| 2025-09-30 | $29.10M 10-Q · filed 2025-11-06 | $48.63M derived: sum of 2 quarters · filed 2026-08-06 | $68.19M 10-Q · filed 2025-11-06 | $89.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $19.53M 10-Q · filed 2026-08-06 | $39.09M 10-Q · filed 2026-08-06 | $60.28M derived: sum of 3 quarters · filed 2026-08-06 | $81.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $19.55M 10-Q · filed 2026-05-07 | $40.75M derived: sum of 2 quarters · filed 2026-05-07 | $62.15M derived: sum of 3 quarters · filed 2026-05-07 | $89.62M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $21.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $42.59M derived: sum of 2 quarters · filed 2026-03-05 | $70.07M derived: sum of 3 quarters · filed 2026-03-05 | $93.10M 10-K · filed 2026-03-05 |
| 2024-09-30 | $21.40M 10-Q · filed 2025-11-06 | $48.88M derived: sum of 2 quarters · filed 2025-11-06 | $71.91M 10-Q · filed 2025-11-06 | $100.58M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $27.48M 10-Q · filed 2025-08-06 | $50.51M 10-Q · filed 2025-08-06 | $79.19M derived: sum of 3 quarters · filed 2025-08-06 | $101.50M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $23.03M 10-Q · filed 2025-05-06 | $51.71M derived: sum of 2 quarters · filed 2025-05-06 | $74.02M derived: sum of 3 quarters · filed 2025-05-06 | $100.05M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $28.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $50.99M derived: sum of 2 quarters · filed 2025-03-10 | $77.02M derived: sum of 3 quarters · filed 2025-03-10 | $103.66M 10-K · filed 2025-03-10 |
| 2023-09-30 | $22.31M 10-Q · filed 2024-11-06 | $48.34M derived: sum of 2 quarters · filed 2024-11-06 | $74.98M 10-Q · filed 2024-11-06 | $101.20M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $26.03M 10-Q · filed 2024-08-06 | $52.67M 10-Q · filed 2024-08-06 | $78.89M derived: sum of 3 quarters · filed 2024-08-06 | $101.94M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $26.64M 10-Q · filed 2024-05-07 | $52.86M derived: sum of 2 quarters · filed 2024-05-07 | $75.91M derived: sum of 3 quarters · filed 2024-05-07 | $100.00M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $26.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $49.27M derived: sum of 2 quarters · filed 2024-03-12 | $73.36M derived: sum of 3 quarters · filed 2024-03-12 | $111.49M 10-K · filed 2024-03-12 |
| 2022-09-30 | $23.05M 10-Q · filed 2023-11-02 | $47.14M derived: sum of 2 quarters · filed 2023-11-02 | $85.27M 10-Q · filed 2023-11-02 | $123.58M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $24.09M 10-Q · filed 2023-08-03 | $62.21M 10-Q · filed 2023-08-03 | $100.53M derived: sum of 3 quarters · filed 2023-08-03 | $135.13M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $38.13M 10-Q · filed 2023-05-04 | $76.44M derived: sum of 2 quarters · filed 2023-05-04 | $111.05M derived: sum of 3 quarters · filed 2023-05-04 | $142.16M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $38.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $72.92M derived: sum of 2 quarters · filed 2023-03-09 | $104.03M derived: sum of 3 quarters · filed 2023-03-09 | $132.68M 10-K · filed 2023-03-09 |
| 2021-09-30 | $34.60M 10-Q · filed 2022-11-02 | $65.72M derived: sum of 2 quarters · filed 2022-11-02 | $94.36M 10-Q · filed 2022-11-02 | $128.65M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $31.11M 10-Q · filed 2022-08-04 | $59.76M 10-Q · filed 2022-08-04 | $94.05M derived: sum of 3 quarters · filed 2022-08-04 | $115.60M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $28.65M 10-Q · filed 2022-05-04 | $62.94M derived: sum of 2 quarters · filed 2022-05-04 | $84.49M derived: sum of 3 quarters · filed 2022-05-04 | $105.76M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $34.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $55.84M derived: sum of 2 quarters · filed 2022-03-10 | $77.11M derived: sum of 3 quarters · filed 2022-03-10 | $97.83M 10-K · filed 2022-03-10 |
| 2020-09-30 | $21.56M 10-Q · filed 2021-11-04 | $42.83M derived: sum of 2 quarters · filed 2021-11-04 | $63.55M 10-Q · filed 2021-11-04 | $81.98M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $21.27M 10-Q · filed 2021-08-05 | $41.99M 10-Q · filed 2021-08-05 | $60.43M derived: sum of 3 quarters · filed 2021-08-05 | $74.93M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $20.72M 10-Q · filed 2021-05-10 | $39.16M derived: sum of 2 quarters · filed 2021-05-10 | $53.66M derived: sum of 3 quarters · filed 2021-05-10 | |
| 2019-12-31 | $18.44M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $32.94M derived: sum of 2 quarters · filed 2021-03-23 | $54.04M 10-K · filed 2021-03-23 | |
| 2019-09-30 | $14.50M 10-Q · filed 2020-11-25 | $35.61M 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |